CD178/FASLG: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of CD178/FASLG. The page also collects GeneMedi's different modalities and formats products for CD178 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CD178 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
This gene is a member of the tumor necrosis factor superfamily. The primary function of the encoded transmembrane protein is the induction of apoptosis triggered by binding to FAS. The FAS/FASLG signaling pathway is essential for immune system regulation, including activation-induced cell death (AICD) of T cells and cytotoxic T lymphocyte induced cell death. It has also been implicated in the progression of several cancers. Defects in this gene may be related to some cases of systemic lupus erythematosus (SLE). Alternatively spliced transcript variants have been described. [provided by RefSeq, Nov 2014]
Target ID | GM-T64245 |
Target Name | CD178 |
Gene ID | 356,14103,25385,574159,442968,493945,407111,100052326 |
Gene Symbol and Synonyms | ALPS1B,APT1LG1,APTL,CD178,CD95-L,CD95L,Fas-L,FASL,FASLG,gld,TNFSF6,TNLG1A |
Uniprot Accession | P48023,P36940,P63307,Q861W5 |
Uniprot Entry Name | TNFL6_HUMAN,TNFL6_MACMU,TNFL6_RAT,TNFL6_FELCA |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target, INN Index, Cytokine Target |
Disease | Malignant neoplasm of bladder |
Gene Ensembl | ENSG00000117560 |
Target Classification | N/A |
Pre-made CD178-specific INN-index biosimilar (antibody&conjugates)
Anti-CD178 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Cat No. | Products Name (INN Index) | INN Name | Previous Name | Target | Format | Detail |
GMP-Bios-INN-741 | Pre-Made Asunercept Biosimilar, Fusion Protein targeting FASLG/CD178 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting ALPS1B/APT1LG1/APTL/CD95-L/CD95L/FASL/TNFSF6/TNLG1A | asunercept | FASLG/CD178 | Fusion Protein | Detail |
Click to check more INN-indexed antibody & protein biosimilar
Pre-made anti-CD178 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-CD178 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CD178 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Antibody Name | Species | Format | Classified by tag | Detail |
Anti-CD178/FASLG monoclonal antibody | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | mab | FACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody | Detail |
Multi-species TNFL6/ CD178/ FASLG VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine CD178/FASLG VLP (virus-like particle) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Products Name | Species | Expression Platform | Detail |
CD178/FASLG VLP (virus-like particle) | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | Mammalian cell | Products Developing |
Cytokine Products for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces human, Cynomolgus/ Rhesus macaque, rat, mouse Fas ligand (TNF superfamily, member 6) (FASL) His+Avi (Biotinylated) for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Fas-mediated apoptosis proceeds through the extrinsic pathway via the binding to their respective receptors of ligands, such as FasL, tumor necrosis factor-alpha (TNF-??), lymphotoxin-alpha (LT-??), TNF-like protein-1A (TL1A), and Apo2L/TNF-related apoptosis-inducing ligand (TRAIL). FasL is the ligand for the Fas receptor. TNF-?? and LT-?? are ligands for the TNF superfamily member 1A (TNFR1), TL1A is a ligand for TNF receptor superfamily member 25 (DR3), and TRAIL is a ligand for the TNF receptor superfamily member 10a (DR4/TRAIL-R1) or tumor necrosis factor receptor superfamily member 10b (DR5/TRAIL-R2). These receptors are members of a subset of the TNF receptor super family known as DRs. Engagement of DRs of their cognate ligands promotes recruitment and activation of the apoptosis-initiating proteases caspase-8 and caspase-10 within membrane receptor complexes. This gene is involved in several diseases, including cholangiocarcinoma; chronic myeloid leukemia; diabetes mellitus; pancreatic cancer; and pre-eclampsia.
Target | Species | Antigen Product Name | Bioactivity validation of Antigen | Antibody Product Name | Bioactivity validation of Antibodies | Detail |
FASL | Human, Cynomolgus/Rhesus macaque, rat, mouse | Fas ligand (TNF superfamily, member 6) (FASL) protein | Affintiy&bioactivity validated by ELISA, cell culture validated | Anti-FASL monoclonal antibody | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). | Detail |
Click to check more Cytokine Products
Pre-made FASLG viral vector in GM Promise-ORFTM
Cat No. | Products name | NM ID | Species | Type | Detail |
pGMLP000545 | human FASLG Lentivirus plasmid | NM_000639 | Human | Lentivirus plasmid | Detail |
vGMAP000429 | Human FASLG Adenovirus particle | BC017502 | Human | Adenovirus particle | Detail |
vGMLP000545 | human FASLG Lentivirus particle | NM_000639 | Human | Lentivirus particle | Detail |
pGMAP000429 | Human FASLG Adenovirus plasmid | BC017502 | Human | Adenovirus plasmid | Detail |
pGMLV000739 | Norway rat Faslg Lentivirus plasmid | NM_012908 | Norway Rat | Lentivirus plasmid | Detail |
vGMLV000739 | Norway rat Faslg Lentivirus particle | NM_012908 | Norway Rat | Lentivirus particle | Detail |
pGMLPm004515 | mouse Fasl Lentivirus plasmid | NM_010177 | Mouse | Lentivirus plasmid | Detail |
vGMLPm004515 | mouse Fasl Lentivirus particle | NM_010177 | Mouse | Lentivirus particle | Detail |
About Promise-ORFTM:
Discover the largest collection of ORF/cDNA expression clones from different species, including human, mouse, rat, and more with GeneMedi's Promise-ORFTM. Our collection of ORFs expression clones come in verified mammalian or viral vectors lentivirus, AAV, and adenovirus) and our Promise-ORFTM viral-ready expression vectors make it easy for you to improve viral vector packaging efficiency or directly transfect mammalian cells, resulting in stronger and easier expression detection. Click to search your GOI
If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.